La vendita allo scoperto per NeuroOne Medical Tech dà agli investitori un'idea del grado in cui gli investitori stanno scommettendo sul declino delle azioni di NeuroOne Medical Tech. I dati relativi alle vendite allo scoperto vengono aggiornati ogni due settimane.

NeuroOne Medical Tech (NASDAQ:NMTC) Azioni, Report sulle vendite allo scoperto

NeuroOne Medical Tech

NeuroOne Medical Technologies Corp operates as a medical technology company. It is focused on the development and commercialization of thin-film electrode technology for continuous electroencephalogram (cEEG) and stereoelectrocencephalography (sEEG) recording, brain stimulation, and ablation solutions for patients suffering from brain-related disorders. The company business is in one operating segment, which is the business of development and commercialization of products related to comprehensive neuromodulation cEEG and sEEG recording, monitoring, ablation, and brain stimulation solutions.

NeuroOne Medical Technologies Corporation - Common Stock

NeuroOne Medical Technologies Corp

U.S. stock markets experienced a downturn on Wednesday, with the Nasdaq Composite dropping over 110 points to 19,070.48, a decline of 0.6% over the day. The Dow decreased by 0.3% to 44,722.06, while the S&amp;P 500 fell 0.4% to 5,998.74. 
These are the top stocks that gained the attention of retail traders and investors throughout the day.
Symbotic Inc.&nbsp;(NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/SYM#NASDAQ">SYM</a>)
Symbotic&#8217;s stock plunged 35.86% to close at $24. The stock hit an intraday high of $25.47 and a low of $21.78, with a 52-week range of $59.82 to $17.11. The sharp decline followed the company&#8217;s announcement of a <a href="https://www.benzinga.com/24/11/42213634/symbotic-stock-plummets-26-after-delayed-filing-and-revenue-errors">delay in filing its Annual Report</a> on Form 10-K. The delay was attributed to the need for more time to assess revenue recognition errors and address internal control weaknesses.
Unusual Machines, Inc. (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/UMAC#NYSE">UMAC</a>)
See Also:&nbsp;<a href="https://www.benzinga.com/markets/commodities/24/11/42164230/amid-trumps-drill-baby-drill-pledge-strategist-predicts-us-oil-supply-will-see-marginal-increase-does-the-world-need-that-much-oil?itm_source=parsely-api" target="_blank" rel="noreferrer noopener">Amid Trump&#8217;s &#8216;Drill Baby, Drill&#8217; Pledge, Strategist Predicts US Oil Supply Will See &#8216;Marginal&#8217; Increase:</a>
Unusual Machines saw its stock soar by 83.99% to $9.77, reaching an intraday high of $11.67 and a low of $7.19, with a 52-week high of $11.67 and a low of $0.98. The surge came after the company announced the <a href="https://www.benzinga.com/24/11/42215044/unusual-machines-appoints-donald-trump-jr-to-its-advisory-board-whats-going-on">appointment</a> of Donald Trump Jr. to its advisory board, a move aimed at bolstering its position in the drone industry.
VCI Global Ltd&nbsp;(NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/VCIG#NASDAQ">VCIG</a>)
VCI Global&#8217;s stock skyrocketed 125.27% to $4.10, with an intraday high of $7.74 and a low of $2.33, and a 52-week range of $179.83 to $1.38. The significant rise followed the announcement of a conditional $24 million <a href="https://www.benzinga.com/news/24/11/42218314/why-vci-global-vcig-stock-is-up-90-today">Letter of Award for a data center project</a> in Malaysia. The project, led by the subsidiary V-Gallant Sdn. Bhd., aims to position Malaysia as a top AI hub.
Pony AI Inc.&nbsp;(NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/PONY#NASDAQ">PONY</a>)
Pony AI&#8217;s shares fell 7.69% to $12, with an intraday high of $15.74 and a low of $11.95, matching its 52-week range. The decline came as the company announced the pricing of its <a href="https://www.benzinga.com/news/ipos/24/11/42228125/pony-ai-stock-falls-over-7-after-ipo-pricing-at-13-rebounds-nearly-3-in-after-hours">initial public offering</a> at $13 per ADS. The offering includes 20 million ADSs, with an option for underwriters to purchase an additional 3 million.
Tesla Inc.&nbsp;(NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/TSLA#NASDAQ">TSLA</a>)
Tesla&#8217;s stock dipped 1.58% to close at $332.89, with an intraday high of $342.55 and a low of $326.59, and a 52-week range of $361.92 to $138.8. The decline came as the company <a href="https://www.benzinga.com/markets/24/11/42207185/tesla-sweetens-referral-program-allowing-customers-to-earn-up-to-10000-as-elon-musks-ev-giant-races-to-500k-q4-delivery-target">revamped its referral program</a> in North America, offering enhanced discounts and rewards as it aims to meet its fourth-quarter delivery target of 515,000 vehicles.
Prepare for the day&#8217;s trading&nbsp;<a href="https://editorial.benzinga.com/wp-admin/Premarket%20Movers%20&amp;%20News">with top premarket movers and news</a>&nbsp;by Benzinga.
Read Next: 
<ul>
<li><a href="https://www.benzinga.com/24/11/42206614/polygons-pol-token-outshines-bitcoin-ethereum-in-30-day-gains-top-analyst-anticipates-no-major-selling-pressure-in-days-ahead?itm_source=parsely-api" target="_blank" rel="noreferrer noopener">Crypto&#8217;s Next Mega-Rocket? Analyst Forecasts Insane 2725%-6600% Surge For This Coin</a></li>
</ul>
This story was generated using <a href="https://www.benzinga.com/author/benzinga-neuro">Benzinga Neuro</a> and edited by <a href="https://www.benzinga.com/author/shivdeep-dhaliwal" target="_blank" rel="noreferrer noopener">Shivdeep Dhaliwal</a>

Equities

News

Markets

PONY

TSLA

UMAC

VCIG

Symbotic, Unusual Machines, VCI Global, Pony AI, Tesla: Why These 5 Stocks Are On Investors' Radars Today

Pony AI Inc. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/PONY#NASDAQ">PONY</a>) debuted on the Nasdaq Global Select Market today, pricing its initial public offering at $13 per ADS. The offering of 20 million ADSs, along with a 30-day underwriters&#8217; option for 3 million additional ADSs, aims to raise $260 million in gross proceeds.
What Happened: The IPO includes concurrent private placements totaling $153.4 million from strategic investors, bringing the combined gross proceeds to $413.4 million. If underwriters exercise their full option, proceeds could reach $452.4 million.
Pony AI ADRs opened trading at $13 but closed 7.69% lower at $12.00. However, after-hours trading saw a 2.75% rebound to $12.33, according to <a href="https://www.benzinga.com/pro/">data from Benzinga Pro</a>. The offering is expected to close on Friday.
Goldman Sachs, Merrill Lynch, and Deutsche Bank are among the underwriters for the IPO. Pony AI specializes in autonomous driving solutions with operations spanning multiple continents.
Read Next: 
<ul>
<li><a href="https://www.benzinga.com/markets/equities/24/11/42227972/softbank-secures-bigger-openai-stake-with-1-5b-employee-share-buyout-report">SoftBank Secures Bigger OpenAI Stake With $1.5B Employee Share Buyout: Report</a></li>
</ul>
Image Via Shutterstock 
Disclaimer:&nbsp;This content was partially produced with the help of AI tools and was reviewed and published by Benzinga editors.

Pony AI Stock Falls Over 7% After IPO Pricing At $13, Rebounds Nearly 3% In After Hours

Leading cryptocurrencies rallied ahead of Thanksgiving, shrugging off sell-offs in the stock market.
<figure class="wp-block-table"> 
<table>
<tbody>
<tr>
<td>Cryptocurrency</td>
<td>Gains +/-</td>
<td>Price (Recorded at 7:45 p.m. ET)</td>
</tr>
<tr>
<td>Bitcoin (CRYPTO: <a class="ticker" href="https://www.benzinga.com/quote/btc/usd">BTC</a>)</td>
<td>+4.49%</td>
<td>$96,156.90</td>
</tr>
<tr>
<td>Ethereum (CRYPTO: <a class="ticker" href="https://www.benzinga.com/quote/eth/usd">ETH</a>) &nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;</td>
<td>+9.94%</td>
<td>$3,652.83</td>
</tr>
<tr>
<td>Dogecoin (CRYPTO: <a class="ticker" href="https://www.benzinga.com/quote/doge/usd">DOGE</a>)&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;</td>
<td>+4.81%</td>
<td>$0.4026</td>
</tr>
</tbody>
</table>
</figure>
What Happened: Bitcoin began to surge in the early morning hours, reaching an intraday peak of $97,357. The rally reversed the corrective action that halted the leading cryptocurrency&#8217;s march to $100,000.
Ethereum, the second-largest cryptocurrency, outshone its senior partner with nearly 10% gains over the last 24 hours. The uptick boosted its weekly returns to 17%, compared to Bitcoin&#8217;s 1.34%.
Over $261 million were liquidated in the past 24 hours, with downside bets accounting for $182 million in losses.
Speculative interest rose as Open Interest, or the money locked in unsettled derivatives contracts, increased 14.62% for Ethereum, and 2.95% for Bitcoin.
The number of traders taking long positions for Bitcoin surged against those taking downside bets, according to the Long/Shorts Ratio.
The "Extreme Greed" sentiment strengthened from 75 to 77 over the last 24 hours, according to the reading of the Crypto Fear &amp; Greed Index.
Top Gainers (24-Hours)
<figure class="wp-block-table"> 
<table>
<tbody>
<tr>
<td>Cryptocurrency</td>
<td>Gains +/-</td>
<td>Price (Recorded at 7:45 p.m. ET)</td>
</tr>
<tr>
<td>Ethereum Name Service (ENS)</td>
<td>+64.56%</td>
<td>$36.36</td>
</tr>
<tr>
<td>Uniswap (UNI)</td>
<td>+22.28%</td>
<td>$13.25</td>
</tr>
<tr>
<td>Ethena (ENA)</td>
<td>+20.16%</td>
<td>$0.719</td>
</tr>
</tbody>
</table>
</figure>
The global cryptocurrency market capitalization stood at $3.34 trillion, following a jump of 4.18% in the last 24 hours.
Stock market investors locked in gains ahead of the Thanksgiving holiday. The Dow Jones Industrial Average reversed 138.25 points, or 0.31%, to close at 44,722.06. The S&amp;P 500 slid 0.38% to end at 5,998.74, while the tech-focused Nasdaq Composite pulled back 0.60% to close at 19,060.48.
In other news, the Personal Consumption Expenditures (PCE) price index, the Federal Reserve&#8217;s most reliable inflation measure, <a href="https://www.benzinga.com/economics/macro-economic-events/24/11/42216384/feds-favorite-inflation-gauge-heats-up-as-predicted-personal-incomes-soar-december-interest-rate-cut-in-doubt">increased in October</a> but met expert forecasts.
Traders priced in a 64.7% chance of a 0.25% rate cut in next month's FOMC meeting, up from 59.4% a day earlier, <a href="https://www.cmegroup.com/markets/interest-rates/cme-fedwatch-tool.html">according </a>to the CME FedWatch tool.
U.S. markets will remain shut on Thursday due to Thanksgiving.
See More: <a href="https://www.benzinga.com/money/best-crypto-scanners">Best Cryptocurrency Scanners</a>
Analyst Notes: Noted on-chain analytics firm CryptoQuant stated that Bitcoin's cycle was still far from the "Extreme Bull" phase, suggesting potential for further growth.
It added that price drawdowns would eventually follow, as history has shown, allowing players who missed jumping in earlier another shot.
<figure class="wp-block-embed is-type-rich is-provider-twitter wp-block-embed-twitter"> 
<div class="wp-block-embed__wrapper">
<blockquote class="twitter-tweet" data-width="500" data-dnt="true">Is it too late to buy in? Bitcoin has surged 34% in November &#39;24, with the bull run in full swing. The CryptoQuant Cycle Indicator shows that Cycle Peak hasn&#39;t reached the Extreme Bull phase yet, indicating there&#39;s still potential for growth. How can you enter? A thread &#x1f447; <a href="https://t.co/DCIovZzuTI">pic.twitter.com/DCIovZzuTI</a>
&mdash; CryptoQuant.com (@cryptoquant_com) <a href="https://twitter.com/cryptoquant_com/status/1861873739639791786?ref_src=twsrc%5Etfw">November 27, 2024</a></blockquote>
<script async src="https://platform.twitter.com/widgets.js" charset="utf-8"></script></div>
</figure>
Widely-followed cryptocurrency analyst Ali Martinez issued $6,000 as a mid-term target for Ethereum while setting $10,000 as the long-term goal.
<figure class="wp-block-embed is-type-rich is-provider-twitter wp-block-embed-twitter"> 
<div class="wp-block-embed__wrapper">
<blockquote class="twitter-tweet" data-width="500" data-dnt="true">Our mid-term target for <a href="https://twitter.com/hashtag/Ethereum?src=hash&amp;ref_src=twsrc%5Etfw">#Ethereum</a> <a href="https://twitter.com/search?q=%24ETH&amp;src=ctag&amp;ref_src=twsrc%5Etfw">$ETH</a> remains $6,000&#8230; Long-term target: $10,000! <a href="https://t.co/X4lodGGIVY">https://t.co/X4lodGGIVY</a> <a href="https://t.co/siQsJzelzE">pic.twitter.com/siQsJzelzE</a>
&mdash; Ali (@ali_charts) <a href="https://twitter.com/ali_charts/status/1861917671333216569?ref_src=twsrc%5Etfw">November 27, 2024</a></blockquote>
<script async src="https://platform.twitter.com/widgets.js" charset="utf-8"></script></div>
</figure>
Another influential analyst, Rekt Capital, stated that Ether needs a weekly close above the $3,700 resistance to "new highs not seen since late 2021."
<figure class="wp-block-embed is-type-rich is-provider-twitter wp-block-embed-twitter"> 
<div class="wp-block-embed__wrapper">
<blockquote class="twitter-tweet" data-width="500" data-dnt="true"><a href="https://twitter.com/search?q=%24ETH&amp;src=ctag&amp;ref_src=twsrc%5Etfw">$ETH</a> Ethereum has revisited the ~$3700 resistance of its main market structure (light blue) Now needs a Weekly Close above this resistance to break out into macro trend continuation to new highs not seen since late 2021<a href="https://twitter.com/hashtag/ETH?src=hash&amp;ref_src=twsrc%5Etfw">#ETH</a> <a href="https://twitter.com/hashtag/Crypto?src=hash&amp;ref_src=twsrc%5Etfw">#Crypto</a> <a href="https://twitter.com/hashtag/Ethereum?src=hash&amp;ref_src=twsrc%5Etfw">#Ethereum</a> <a href="https://t.co/gt6w65hexJ">https://t.co/gt6w65hexJ</a> <a href="https://t.co/BE0E2LfW70">pic.twitter.com/BE0E2LfW70</a>
&mdash; Rekt Capital (@rektcapital) <a href="https://twitter.com/rektcapital/status/1861922836501110976?ref_src=twsrc%5Etfw">November 27, 2024</a></blockquote>
<script async src="https://platform.twitter.com/widgets.js" charset="utf-8"></script></div>
</figure>
Read Next:&nbsp;&nbsp;&nbsp;&nbsp;
<ul>
<li><a href="https://www.benzinga.com/markets/cryptocurrency/24/11/42211674/bitcoin-at-93000-crash-or-pause-bullish-outlook-for-2025-says-10x-research">Bitcoin At $93,000—Crash Or Pause? &#8216;Bullish Outlook For 2025,&#8217; Says 10x Research</a></li>
</ul>

Coverage of Bitcoin, Etherum, Ripple and all the latest digital currencies.

Cryptocurrency

Movers

Trading Ideas

$BTC

$DOGE

$ETH

Bitcoin, Ethereum, Dogecoin Surge As Traders Raise Risk Appetite Ahead Of Thanksgiving: Analyst Sets Mid-Term Price Target For ETH At $6K

OpenAI enables employees to sell up to $1.5 billion worth of shares in a tender offer led by SoftBank Group (OTC:<a class="ticker" href="https://www.benzinga.com/stock/SFTBY#OTC">SFTBY</a>) (OTC:<a class="ticker" href="https://www.benzinga.com/stock/SFTBF#OTC">SFTBF</a>). 
What Happened: The transaction, set to close by Dec 24, allows SoftBank to deepen its stake in the AI leader while offering liquidity to current and former employees, <a href="https://www.cnbc.com/2024/11/26/openai-gets-1point5-billion-investment-from-softbank-in-tender-offer.html">reported</a> CNBC, citing people familiar with the matter.
The deal, priced at $210 per share, aligns with OpenAI&#8217;s <a href="https://www.benzinga.com/news/24/10/41149788/openai-valuation-soars-to-157b-in-latest-funding-round">recent $157 billion valuation</a>. SoftBank CEO Masayoshi Son drove the move, following a $500 million investment in OpenAI's last funding round. This marks another step in Son's aggressive AI strategy, with SoftBank's Vision Fund 2 also backing startups like Glean and Perplexity.
OpenAI, backed by $13 billion in funding from investors including Microsoft Corp (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/MSFT#NASDAQ">MSFT</a>) and NVIDIA Corp (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/NVDA#NASDAQ">NVDA</a>), has emphasized the importance of such tender offers amid a dormant IPO market. 
This initiative reflects the company&#8217;s commitment to employee satisfaction and continued capital-raising to sustain its growth in the <a href="https://www.benzinga.com/startups/24/10/41312615/investors-pour-billions-into-openai-whats-driving-this-unprecedented-surge-in-funding">competitive generative AI market</a>.
SoftBank and OpenAI did not immediately respond to <a href="http://pro.benzinga.com/" target="_blank" rel="noreferrer noopener">Benzinga</a>'s request for comment.
Read Next: 
<ul>
<li><a href="https://www.benzinga.com/24/11/42227693/blackrock-set-to-acquire-private-credit-manager-hps-for-12b-report">BlackRock Set To Acquire Private Credit Manager HPS For $12B: Report</a></li>
</ul>
Image Via Shutterstock 
Disclaimer: This content was partially produced with the help of AI tools and was reviewed and published by Benzinga editors.

Startups

Tech

MSFT

NVDA

SFTBF

SFTBY

SoftBank Secures Bigger OpenAI Stake With $1.5B Employee Share Buyout: Report

Mark Zuckerberg, CEO of Meta Platforms Inc. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/META#NASDAQ">META</a>), reportedly met with President-elect Donald Trump on Wednesday.
What Happened: The meeting took place at Trump's Mar-a-Lago resort in Florida, but specific details remain undisclosed, <a href="https://www.nytimes.com/live/2024/11/27/us/trump-news?smid=url-share#981f2720-c62f-5720-873f-81e07a6c31c8">reported</a> the New York Times, citing two people briefed on the meeting.
Earlier this year, Trump had threatened legal action against Zuckerberg if elected. He has also accused the Meta CEO of plotting against him while appearing friendly during visits to the Oval Office.
See Also: <a href="https://www.benzinga.com/news/earnings/24/11/42201885/dell-technologies-shares-drop-after-q3-revenue-misses-estimates-details?itm_source=parsely-api">Dell Technologies Shares Drop After Q3 Revenue Misses Estimates: Details</a>
However, <a href="https://www.benzinga.com/news/24/09/40785288/did-mark-zuckerberg-really-say-no-way-i-can-vote-for-a-democrat-in-this-election-to-trump">Zuckerberg praised his resilience</a> following an assassination attempt in July. Later, Trump said that Zuckerberg expressed support for him over Democrats, a <a href="https://www.benzinga.com/news/24/09/40785288/did-mark-zuckerberg-really-say-no-way-i-can-vote-for-a-democrat-in-this-election-to-trump">statement Meta denied</a>.
The Meta CEO is not alone in visiting Mar-a-Lago. Tesla and SpaceX CEO Elon Musk, who <a href="https://www.benzinga.com/markets/24/11/41866189/elon-musk-joined-trumps-call-with-zelenskyy">supported Trump&#8217;s campaign</a>, also spent time at the resort following the election. 
Meta did not immediately respond to Benzinga&#8217;s request for comments.
Why It Matters: Historically, Zuckerberg and Trump have met multiple times, including a reported secret dinner with billionaire Peter Thiel in 2019.
Facebook had suspended Trump&#8217;s account after the Capitol insurrection. Meta reinstated his accounts in 2023.
Following Trump's election victory, <a href="https://www.benzinga.com/news/24/11/41796344/tim-cook-mark-zuckerberg-and-jeff-bezos-congratulate-trump-whats-next-for-the-tech-giants">Zuckerberg congratulated him</a> while expressing optimism about future collaborations. Meta's share price soared on Nov. 7, 2024, reaching $591.70, two days after Election Day.
Price Action: Meta&#8217;s stock declined by 0.76% on Wednesday, ending the day at $569.20, but edged up by 0.11% in after-hours trading. Year-to-date, Meta shares have climbed 64.37%, significantly outpacing the Nasdaq 100 index&#8217;s 25.39% gain over the same period, according to <a href="https://benzinga.grsm.io/lxquj26b2sag">Benzinga Pro data</a>.
Photos courtesy: Flickr and Shutterstock
Read Next:
<ul>
<li><a href="https://www.benzinga.com/24/11/42208148/russian-hackers-launch-widespread-cyber-assault-using-firefox-and-windows-zero-days-what-you-need-to-know-about-the-romcom-exploit?itm_source=parsely-api">Russian Hackers Launch Widespread Cyber Assault Using Firefox And Windows Zero-Days: What You Need To Know About The RomCom Exploit</a></li>
</ul>
Disclaimer:&nbsp;This content was partially produced with the help of AI tools and was reviewed and published by Benzinga editors.

Politics

Media

Mark Zuckerberg And Trump Reportedly Met At Mar-A-Lago

On Wednesday, Cathie Wood-led Ark Invest made some notable trades. The most prominent among these were in Amazon.com Inc (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/AMZN#NASDAQ">AMZN</a>), Advanced Micro Devices Inc. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/AMD#NASDAQ">AMD</a>), Palantir Technologies Inc. (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/PLTR#NYSE">PLTR</a>), and Block Inc. (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/SQ#NYSE">SQ</a>).
The Amazon Trade
Ark Invest bought 82,735 shares in Amazon.com Inc. through ARK Innovation ETF (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/ARKK#NYSE">ARKK</a>) and ARK Space Exploration &amp; Innovation ETF (BATS:<a class="ticker" href="https://www.benzinga.com/stock/ARKX#BATS">ARKX</a>). This move comes in the wake of Amazon&#8217;s recent <a href="https://www.benzinga.com/24/11/42176396/amazon-anthropic">$8 billion investment</a> in artificial intelligence research and development company, Anthropic. As part of the investment, Anthropic named Amazon Web Services as its primary training partner and cloud provider. The investment is expected to be mutually beneficial. Based on the closing price of $205.74, the value of the trade is approximately $17.02 million.
The AMD Trade
Ark Invest also purchased 127,363 shares of Advanced Micro Devices Inc. through ARKK and ARKX. Despite the company&#8217;s <a href="https://www.benzinga.com/24/11/42193158/amds-downward-spiral-is-a-reversal-on-the-horizon-or-just-a-blip">recent struggles</a>, Ark Invest seems to see potential in the tech giant. The value of the trade, calculated from the closing price of $136.24, is approximately $17.35 million. AMD stock at $142.68 faces bearish momentum, trading below key moving averages. A slight bullish signal from the 8-day SMA contrasts with weak RSI and MACD indicators. Market share gains offer hope, but sustainability remains uncertain.
The Palantir Trade
Ark Invest sold 100,804 shares of Palantir Technologies Inc. through ARKK. Despite the sale, it&#8217;s worth noting that Wedbush analyst Dan Ives <a href="https://www.benzinga.com/markets/24/11/42179988/dan-ives-defends-75-palantir-target-amid-ai-revolution-and-revenue-surge-haters-will-continue-to-hate">recently reaffirmed</a> his $75 price target on Palantir, citing strong growth potential amid the AI revolution. The value of the trade, based on the closing price of $66.05, is approximately $6.66 million.
The SQ Trade
See Also: <a href="https://www.benzinga.com/24/11/42156817/tesla-rivian-settle-battery-tech-theft-dispute-after-nearly-4-years?itm_source=parsely-api" target="_blank" rel="noreferrer noopener">Tesla, Rivian Signal End To 4-Year Legal Battle Over Alleged Trade Secrets Theft</a>
Ark Invest sold shares of Block Inc., formerly known as Square Inc. The value of the trade, calculated from the closing price of $88.78, is approximately $9.82 million. Ark invested in the Bitcoin (CRYPTO: <a class="ticker" href="https://www.benzinga.com/quote/btc/usd">BTC</a>)-focused firm through ARKK. Ark Invest shared Bitcoin <a href="https://www.benzinga.com/markets/cryptocurrency/24/11/42122886/cathie-woods-3-8-million-bitcoin-vision-met-with-doubt-83-say-not-by-2030">price targets</a> for 2030, ranging from $258,500 (bear case) to $3.8 million (bull case), based on corporate adoption. A Benzinga poll revealed only 17% believe the $3.8 million target is achievable by 2030, with many seeing it as unlikely or delayed. Wood emphasized regulatory clarity and institutional demand as key drivers for Bitcoin&#8217;s future growth.
Other Key Trades:
<ul>
<li>Ark Invest sold shares of Butterfly Network Inc (BFLY) and Repare Therapeutics Inc (RPTX).</li>
<li>Ark Invest bought shares of Pacific Biosciences of California Inc. (PACB) and Illumina Inc. (ILMN).</li>
<li>Ark Invest sold shares of Roblox Corp (RBLX). The firm bought shares of Pinterest Inc (PINS).</li>
</ul>
Read Next: 
<ul>
<li><a href="https://www.benzinga.com/24/11/42206056/bitcoin-ethereum-dogecoin-tumble-as-diamond-hands-lock-in-gains-analyst-anticipates-strong-buyback-pressure-to-follow-sell-pressure?itm_source=parsely-api" target="_blank" rel="noreferrer noopener">Bitcoin, Ethereum, Dogecoin Tumble As &#8216;Diamond Hands&#8217; Lock In Gains: Top Analyst Anticipates BTC Rebound</a></li>
</ul>
This story was generated using <a href="https://www.benzinga.com/author/benzinga-neuro">Benzinga Neuro</a> and edited by <a href="https://www.benzinga.com/author/shivdeep-dhaliwal" target="_blank" rel="noreferrer noopener">Shivdeep Dhaliwal</a>

ETFs

AMZN

ARKK

ARKX

PLTR

Cathie Wood Buys Amazon, AMD Stock — Trims Palantir, Block Holdings Amid AI And Bitcoin Euphoria

BlackRock Inc (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/BLK#NYSE">BLK</a>), the world's largest asset manager with $11.5 trillion in assets, is finalizing a deal to acquire HPS Investment Partners, a prominent private credit firm managing nearly $150 billion.
What Happened: The acquisition, expected to be announced after Thanksgiving, the Financial Times reported citing four people familiar with the matter, could be valued at around $12 billion, surpassing HPS's earlier estimated IPO valuation of $10 billion.
Founded by former Goldman Sachs executive Scott Kapnick, HPS has grown into a major player in private credit, benefiting from traditional banks retreating due to stricter post-crisis regulations.
This move aligns with BlackRock's strategy to expand its alternative assets business, a high-fee segment gaining prominence. The firm recently completed a $12.5 billion deal for Global Infrastructure Partners and agreed to acquire Preqin for £2.55 billion.
If finalized, this acquisition will position BlackRock ahead of competitors like Ares and Blackstone in the burgeoning private credit market. Neither BlackRock nor HPS has commented on the
BlackRock did not immediately respond to&nbsp;<a href="http://pro.benzinga.com/" target="_blank" rel="noreferrer noopener">Benzinga</a>'s request for comment.
Read Next: 
<ul>
<li><a href="https://www.benzinga.com/news/retail-sales/24/11/42225933/black-friday-cyber-monday-shopping-set-to-break-sales-records">Black Friday, Cyber Monday Shopping Set To Break Sales Records</a></li>
</ul>
Image Via Shutterstock 
Disclaimer:&nbsp;This content was partially produced with the help of AI tools and was reviewed and published by Benzinga editors.

BlackRock Set To Acquire Private Credit Manager HPS For $12B: Report

Soundhound AI (SOUN) has been soaring lately with news of voice AI integration, but a recent <a href="https://www.benzinga.com/insights/short-sellers/24/11/42165886/how-is-the-market-feeling-about-soundhound-ai?adt_ei=%7b%7bemail%7d%7d">Benzinga article</a> on highlights the steep rise in short interest – a whopping 24% of all regular shares are shorted and this would take more than three days of normal trading volume to cover.
This means that SOUN is a target for a short squeeze. Why? Because short sellers will have to buy the stock to cover their positions, and this will push prices even higher. So, how might we position for upside here with the limited risk?
Why, the butterfly trade, of course!
Trade structure – the long call butterfly trade
The long call butterfly is a combination of a long call spread, and a short call spread where the short strikes are shared. Here's the trade:
<ul>
<li>Buy to open 1 SOUN 17 Jan 8 calls</li>
<li>Sell to open 2 SOUN 17 Jan 12 calls</li>
<li>Buy to open 1 SOUN 17 Jan 15 calls</li>
</ul>
[<a href="https://www.benzinga.com/pro/checkout/black-friday-24/?utm_source=WebRD-1128">Black Friday Week: Save 60% on Benzinga Pro—The Market's Ultimate Trading Suite</a>]
The total cost of this spread is currently 0.46 at this writing and it is also the maximum risk in the position. There is one caveat here – the distance between the strikes will make this a winning trade even if the stock moves well above $15. Here's why:
In a standard long butterfly spread, the distance between the middles strikes and the outer strikes are the same. This means that if the stock moves dramatically higher when holding the long call butterfly, the entire position would be a loss if held into the expiration date.
This butterfly, however is different.
The spread between the 8 and 12 strikes is $4, while the spread between the 12 and 15 strikes is $3 &#8211; leaving an extra $1 to collect even if prices expand north.
The total potential profit if the price of the stock does not breach $12 would be calculated this way: $12-8 = $4 (distance between the strikes) minus how much we paid for it 0.46 = $3.54 less commissions.
Potentially 600%!
That said, if the prices stay steady, this option position will gradually erode to zero, so manage your risk according to that understanding.
Trade Management
SOUN's relative resistance zone is right around $7.80 (where it sits now) The relative support is near $4.20.
The strategy result provides only two choices to exit the trade:
<ol>
<li>To sell the call butterfly when it is performing at your target parameters. I like the 200%-300% profit range.</li>
<li>To sell the call butterfly when it hits the short strike or hits the loss threshold that is desirable for you. Again, I like the 50% stop here.</li>
</ol>

Elevate your trading game with the market&#8217;s most powerful suite of tools, featuring breaking news, expert insights, and real-time alerts. <a href="https://www.benzinga.com/pro/checkout/black-friday-24/?utm_source=WebRD-1128">Don't miss the Black Friday Week deal—60% off Benzinga Pro!</a>

Opinion

The Perfect Trade For This AI "Short Squeeze"

President-elect Donald Trump said he has had a &#8220;wonderful conversation&#8221; with Mexico&#8217;s President, Claudia Sheinbaum, aimed at curbing migration and drug inflow into the United States.
What Happened: On Wednesday, Trump shared on Truth Social about a productive conversation he had with Sheinbaum. The Mexican President has reportedly agreed to halt migration through Mexico into the United States, effectively securing the Southern Border. The leaders also discussed strategies to curb the massive drug inflow into the U.S. and the country&#8217;s consumption of these drugs.
Trump said, &#8220;She has agreed to stop Migration through Mexico, and into the United States, effectively closing our Southern Border. We also talked about what can be done to stop the massive drug inflow into the United States, and also, U.S. consumption of these drugs. It was a very productive conversation!&#8221;
Trump lauded this agreement as a significant step towards halting the &#8220;illegal invasion&#8221; of the U.S. and expressed his gratitude towards Sheinbaum.
He said, &#8220;Mexico will stop people from going to our Southern Border, effective immediately.&#8221;
See Also:&nbsp;<a href="https://www.benzinga.com/general/education/24/11/42204590/trump-department-of-homeland-security-pick-kristi-noem-owns-ranch-invests-in-energy-gets-book-royalties?itm_source=parsely-api" target="_blank" rel="noreferrer noopener">Trump Department Of Homeland Security Pick Kristi Noem Owns Ranch, Invests In Energy, Gets Book Royalties</a>
Why It Matters: This announcement comes in the backdrop of Trump&#8217;s earlier plans to <a href="https://www.benzinga.com/24/11/42178994/trump-says-he-will-impose-25-tariffs-on-canada-mexico-on-first-day-of-office-and-extra-tariffs-on-china-until-they-pay-attention">impose a 25% tariff</a> on all products from Mexico and Canada. Trump had described the situation at the borders as an &#8220;invasion&#8221; and linked it to rising crime and drug levels.
Sheinbaum had previously responded to Trump&#8217;s tariff threats by <a href="https://www.benzinga.com/markets/cannabis/24/11/42225423/mexico-president-claudia-sheinbaum-to-trump-neither-threats-nor-tariffs-will-solve-your-fentanyl-crisis">emphasizing cooperation</a> over confrontation. She stated that &#8220;neither threats nor tariffs&#8221; would solve the migration or drug abuse issues in the U.S.
The proposed tariffs had also escalated trade tensions between the U.S. and Mexico, causing the Mexican peso to <a href="https://www.benzinga.com/analyst-ratings/analyst-color/24/11/42219612/usmexico-trade-tensions-escalate-as-mexican-peso-hits-august-2022-lows-why-is-auto-industry-most-at-risk">weaken significantly</a>.
Image via Shutterstock
Did You Know?
<ul>
<li>Congress Is Making Huge Investments. <a href="https://www.benzinga.com/gov-trades">Get Tips On What They Bought And Sold Ahead Of The 2024 Election With Our Easy-to-Use Tool</a></li>
</ul>
This story was generated using <a href="https://www.benzinga.com/author/benzinga-neuro">Benzinga Neuro</a> and edited by <a href="https://www.benzinga.com/author/shivdeep-dhaliwal" target="_blank" rel="noreferrer noopener">Shivdeep Dhaliwal</a>

General

Trump Praises 'Wonderful Conversation' With Mexican President Sheinbaum: 'She Has Agreed To Stop Migration'

DBVT

Trading Halt: Halted at 7:50:00 p.m. ET - Trading Halt: Halt News Pending

SLXN

Earnings

Birks Group Mid-Year FY25 EPS C$(0.16) Down From C$(0.08) YoY, Sales C$80.12M Down From C$87.82M YoY

Banco Macro Q3 Net Income Up 293% YoY, Total Deposits Increase 30% YoY

Florida's Department of Health announced plans to award 22 new medical cannabis licenses, a decision that could reshape the state's cannabis industry but is likely to face legal challenges. 
The announcement, posted Tuesday on the agency's website (<a href="https://www.tallahassee.com/story/news/local/state/2024/11/27/florida-picks-22-applicants-to-get-next-medical-marijuana-licenses/76623095007/">via</a> Tallahassee Democrat), comes more than 18 months after applications closed in April 2023.
See Also: <a href="https://www.benzinga.com/markets/cannabis/24/11/42225423/mexico-president-claudia-sheinbaum-to-trump-neither-threats-nor-tariffs-will-solve-your-fentanyl-crisis">Mexico President Claudia Sheinbaum To Trump: &#8216;Neither Threats Nor Tariffs&#8217; Will Solve Your Fentanyl Crisis</a>
The new licenses are a result of a 2017 law mandating an increase in licenses as the number of medical marijuana patients grows, which now surpasses 880,000. This process has attracted significant attention since it marks the first chance for new businesses to enter Florida&#8217;s medical cannabis market since the law&#8217;s enactment.
The department's letters of intent signal approval for 22 businesses out of the 74 that applied last year, each paying a $143,000 application fee. The evaluation process, carried out by consulting firm KPMG, cost the state nearly $1.79 million. However, the letters do not grant immediate operating licenses, leaving room for legal action from applicants who were not selected.
<h3 class="wp-block-heading">Anticipated Legal Battles</h3>
Legal disputes are expected to delay the process, possibly for years, given the competitive nature of <a href="https://www.benzinga.com/24/11/42017405/medical-marijuana-footprint-grows-in-florida-as-legalization-push-fizzles-and-other-new-cannabis-stores-that-launched-sales">Florida's cannabis market. </a>
"Historically, when these sorts of things happen, litigation does occur. You have 22 people that are very happy and 50 people that are not very happy at all," Department of Health spokesperson Jae Williams said in dialogue with The News Service of Florida. 
He also noted the substantial investments made by applicants and the department's responsibility to ensure that approved operators meet high standards for quality.
Applicants have called for legislative intervention to prevent prolonged delays. Attorney Paula Savchenko, who worked with Florida Sports Consultants, Inc.—operating as Belushi's Farm Florida—said the process could stall for months or even years without action.
"If we don't have a legislative fix, we're going to see these licenses held up for anywhere between six months to two years," Savchenko said.
<h3 class="wp-block-heading">Industry Shifts And New Players</h3>
Notable applicants receiving letters include Florida Sports Consultants, Inc., led by actor Jim Belushi, who also operates a cannabis farm in Oregon. Other approved businesses include STIIIZY Florida, LLC, A Good Decision, LLC and Theory Wellness of Florida, LLC. The additions bring Florida closer to doubling its licensed operators, which currently stand at 25, managing over 690 dispensaries statewide.
Quincy-based Trulieve Cannabis Corp. (OTC:<a class="ticker" href="https://www.benzinga.com/stock/TCNNF#OTC">TCNNF</a>), the state's largest medical marijuana operator, welcomed the expansion. 
"We are pleased that the licenses are finally issued, bringing the number of licensees to 47. We continue to look forward to working with the governor and legislature to expand access to safe, lab-tested cannabis for Floridians," the company said in a statement.
<ul>
<li>Get Benzinga's exclusive analysis and the top news about the cannabis industry and markets daily in your inbox for free. Subscribe to our newsletter&nbsp;<a href="https://newsletteremail.benzinga.com/subscribe" target="_blank" rel="noreferrer noopener">here</a>. If you're serious about the business, you can't afford to miss out.</li>
</ul>
<h3 class="wp-block-heading">Broader Context</h3>
The decision to award licenses coincides with <a href="https://www.benzinga.com/markets/cannabis/24/11/41780079/floridas-cannabis-initiative-defeated-trulieve-ceo-kim-rivers-nfls-ricky-williams-and-others-res">the defeat of a proposed constitutional amendment </a>that sought to legalize recreational marijuana. 
The measure received 56% voter approval but fell short of the 60% threshold needed for passage. Governor Ron DeSantis played a significant role in opposing the amendment, which had been heavily supported by industry leaders, including Trulieve.
"The majority of people in the industry would rather have had recreational pass, but we all are pretty confident that it's going to pass sometime in the next two to four years," Savchenko said.
For now, Florida's medical marijuana industry is bracing for the next phase, with new players poised to enter the market and potential legal hurdles still ahead.
Read Next:
<ul>
<li><a href="https://www.benzinga.com/general/health-care/24/11/42222815/cannabis-on-thanksgiving-10-science-backed-benefits-for-a-happier-holiday">Cannabis On Thanksgiving: 10 Science-Backed Benefits For A Happier Holiday</a></li>
</ul>
Cover image made with AI.

Cannabis

Government

TCNNF

Florida To Award 22 New Cannabis Licenses After 18-Month Wait—Legal Battles Ahead?

The Detroit Lions and Dallas Cowboys traditionally play on Thanksgiving, making NFL games a key part of the holiday, alongside family gatherings and feasts. It is also a day off for the <a href="https://www.benzinga.com/etfs/broad-u-s-equity-etfs/23/11/35930411/is-the-stock-market-closed-on-thanksgiving-traders-prepare-for-a-holiday-break">country's major stock markets</a>.
Along with the Lions and Cowboys, four other NFL teams will be featured across three NFL games on Thanksgiving Day.
Lions and Cowboys Thanksgiving Day Games: Dating back to 1934, the Detroit Lions have played in the annual Thanksgiving Day game. The lone exceptions were the 1939 through 1944 seasons that weren&#8217;t played due to World War II. The games have become a staple for the&nbsp;<a href="https://www.benzinga.com/topic/nfl" target="_blank" rel="noreferrer noopener">National Football League.</a>
The idea for the Thanksgiving Day game was&nbsp;<a href="https://www.espn.com/nfl/story/_/id/32646037/nfl-thanksgiving-day-games-history-lions-cowboys-play-every-year-moments-traditions-records" target="_blank" rel="noreferrer noopener">created&nbsp;</a>by former Lions owner&nbsp;G.A. Richards&nbsp;as a way to increase attendance and media hype for the team. Richards purchased the Portsmouth (Ohio) Spartans and moved them to Detroit before the tradition began.
The first Thanksgiving Day game was watched by more than 26,000 fans.
The Dallas Cowboys played on Thanksgiving Day in 1966, beating the Cleveland Browns 26-14. The Cowboys&#8217; first Thanksgiving Day game was attended by 80,259 people. The Cowboys have played a Thanksgiving Day game every year since except 1975 and 1977.
Similar to the Lions, the Cowboys saw the holiday as a way to create more national media attention for the team.
The Lions created the concept, and the game pre-dates the Super Bowl and many of the NFL teams being created, which makes tradition the biggest reason why the Lions and Cowboys play in their respective games annually.
In 2006, the NFL added a prime-time Thanksgiving Day game that features two rotating teams.
Thanksgiving Day Stats:&nbsp;The Lions lost its first Thanksgiving Day game and haven&#8217;t had success in many of the contests: the franchise holds an all-time 37-45-2 record in Thanksgiving Day games. The Lions have lost seven straight Thanksgiving Day games heading into the 2024 contest.
As the creators of the game concept, the Lions have the most Thanksgiving Day wins with 37, but one of the worst records overall.
The Cowboys have had better success in their games, holding an all-time-record of 33-22-1.
While they don&#8217;t play every year, two other teams largely featured are the&nbsp;Chicago Bears&nbsp;and&nbsp;Green Bay Packers, which hold all-time Thanksgiving Day records of 20-15-2 and 15-20-2, respectively. Both the Bears and Packers play on Thursday.
The&nbsp;Jacksonville Jaguars&nbsp;are the only NFL team to never play in a Thanksgiving Day game. Several teams have never won on Thanksgiving Day, with the Tampa Bay Buccaneers and Cincinnati Bengals each holding a 0-1 record.
Read Also: <a href="https://www.benzinga.com/general/sports-betting/24/08/40555085/sports-illustrated-predicts-detroit-lions-to-win-super-bowl-heres-how-much-100-bet-could-p">Sports Illustrated Predicts Detroit Lions To Win Super Bowl: Here&#8217;s How Much $100 Bet Could Pay If History Is Made</a>
2024 Thanksgiving Day Games:&nbsp;Here&#8217;s a look at the&nbsp;three 2024 Thanksgiving Day games, how to watch and the betting odds.
<ul>
<li>Chicago Bears (4-7) at Detroit Lions (10-1): 12:30 p.m. ET on CBS, a unit of Paramount Global (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/PARA#NASDAQ">PARA</a>)(NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/PARAA#NASDAQ">PARAA</a>)</li>
<li>New York Giants (2-9) at Dallas Cowboys (4-7): 4:30 p.m. ET on FOX, a unit of Fox Corporation (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/FOX#NASDAQ">FOX</a>)(NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/FOXA#NASDAQ">FOXA</a>)</li>
<li>Miami Dolphins (5-6) at Green Bay Packers (8-3): 8:20 p.m. on NBC, a unit of Comcast Corp (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/CMCSA#NASDAQ">CMCSA</a>)</li>
</ul>
The Giants are 7-6-3 all-time in Thanksgiving Day matches and the Dolphins are 5-2 all-time on Thanksgiving Day.
All three home teams are the favorites in their Thursday games. Betting odds from DraftKings Inc (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/DKNG#NASDAQ">DKNG</a>) show the Lions favored by 9.5 points, the Cowboys favored by 3.5 points and the Packers favored by 3.5 points.
Betting on all three favorites to win pays out with odds of +212, which would turn $100 bet into a profit of $212 if the Lions, Cowboys and Packers all win. Betting on all three favorites to cover the spread and win by the totals listed above would pay out at +638, turning $100 bet into a profit of $638 if all three teams cover.
Betting favorites on Thanksgiving Day are 48-9 straight up and 38-19 against the spread since 2004, according to <a href="https://www.actionnetwork.com/nfl/nfl-thanksgiving-betting-trends-stats-notes-action-network-betting-primer-2024">data </a>from Action Network.
A win by the Bears could be one of the biggest upsets on Thanksgiving Day since 1980 depending on where the spread closes. The current record is the Dolphins beating the Cowboys as 10-point underdogs in 1993. The Packers win over the Lions in 2023 as 8.5-point underdogs ranks second.
Why It's Important: The Thanksgiving Day NFL games could be part of a huge week for sportsbooks. Macquarie analyst Chad Beynon estimates $4.5 billion will be bet by U.S. bettors over Thanksgiving week from Nov. 25 to Dec. 1, as <a href="https://www.casino.org/news/thanksgiving-football-feast-4-5b-in-wagers-expected-this-week/">reported </a>by Casino.org.
This figure would be up 11% year-over-year and comes with a record 38 states and Washington D.C. allowing legal sports betting for this year's Thanksgiving Day games.
Prime-time games, which typically occur at nighttime often see increased betting with more viewers watching. The three Thanksgiving Day games could all be treated like prime-time games according to Beynon.
The Thanksgiving Day games feature the red-hot Lions who have won nine games in a row and are the current betting favorites to win Super Bowl LIX. The Lions are one of <a href="https://www.benzinga.com/general/sports-betting/24/09/40720484/which-4-teams-have-never-reached-the-super-bowl-betting-payouts-if-history-is-made-in-2024">only four teams </a>to never make a Super Bowl appearance.
DraftKings lists the Lions as the Super Bowl favorites at +250, ranking ahead of the Kansas City Chiefs (+450), who are seeking a third-straight championship. The Packers rank sixth with odds of +1,600 and the Dolphins have odds of +9,000.
The other Thursday teams (Giants, Bears, Cowboys) all have odds of +100,000 to win Super Bowl LIX as all will likely miss making the NFL Playoffs.
Read Next: 
<ul>
<li><a href="https://www.benzinga.com/general/sports/24/11/42101566/trump-dance-takes-over-sports-celebrations-move-over-griddy-gronk-spike-athletes-are-paying-tribute-or-poking-fun-at-president-elect">Trump Dance Takes Over Sports Celebrations: Move Over Griddy, Gronk Spike, Athletes Are Paying Tribute (Or Poking Fun) At President-Elect</a></li>
</ul>
This article was previously published by Benzinga and has been updated.
This image used was created using artificial intelligence MidJourney.

Entertainment

Sports Betting

Sports

CMCSA

DKNG

FOXA

PARA

PARAA

Here's Why The Detroit Lions, Dallas Cowboys Always Have Thanksgiving Day NFL Games

FRST

Primis Financial Gets Nasdaq Notice Due To Delayed 10-Q Filing

Quinlan will continue serving on the Board. John Ratigan, Comtech's President and CEO, will report directly to Traub and they will be working closely together.
In addition, former U.S. Army Chief Information Officer, Lieutenant General (Retired) Bruce T. Crawford, has been elected to serve as Lead Independent Director.
&nbsp;

Management

CMTL

Comtech Telecommunications Names Kenneth Traub As Executive Chairman; Mark Quinlan Has Stepped Down As Chairman Of Board

The study found that twice-yearly lenacapavir for pre-exposure prophylaxis (PrEP) was highly efficacious at reducing HIV infections, reducing them by 96% compared to background HIV incidence.&nbsp;
Twice-yearly lenacapavir for PrEP also demonstrated superiority to once-daily Truvada&#xAE; (emtricitabine 200 mg and tenofovir disoproxil fumarate 300 mg; F/TDF) for PrEP and was generally well-tolerated, with no significant or new safety concerns identified.&nbsp;
&nbsp;

GILD

Gilead Says NEJM Published Full Results From Pivotal Phase 3 Purpose 2 Trial Evaluating Twice-yearly Lenacapavir

AREB

American Rebel Receives Delinquency Notification Letter From Nasdaq

PMEC

Primech Holdings Gets Nasdaq Minimum Bid Price Requirement Extension Until May 12, 2025, To Regain Compliance

<a href="https://investorplace.com">InvestorPlace - Stock Market News, Stock Advice &amp; Trading Tips</a>
NeuroOne Medical Tech (NASDAQ:<a href="https://investorplace.com/stock-quotes/nmtc-stock-quote/">NMTC</a>) just reported results for the second quarter of 2024.<ul><li>NeuroOne Medical Tech reported earnings per share of -11 cents. This was below the analyst estimate for EPS of -10 cents.</li><li>The company reported revenue of $1.38 million.</li><li>This was 19% worse than the analyst estimate for revenue of $1.70 million.</li></ul><div>InvestorPlace Earnings is a project that leverages data from <a href="https://www.tradesmith.com">TradeSmith</a> to automate coverage of quarterly earnings reports. InvestorPlace Earnings distills key takeaways including earnings per share and revenue, as well as how a company stacks up to analyst estimates. These articles are published without human intervention, allowing us to inform our readers of the latest figures as quickly as possible. To report any concerns or inaccuracies, please contact us at <a href="mailto:editor@investorplace.com">editor@investorplace.com</a>.</div><h3>More From InvestorPlace</h3>
		<ul><li>
						<a href="https://investorplace.com/2023/10/no-1-ai-investment-might-be-this-company-youve-never-heard-of/?cid=MKT764787&amp;eid=MKT802110">The #1 AI Investment Might Be This Company You&rsquo;ve Never Heard Of</a>
					</li>
																<li>
						<a href="https://investorplace.com/2023/07/elon-musks-project-omega-stuns-silicon-valley-insiders/?cid=MKT738510&amp;eid=MKT766411">Musk&rsquo;s &ldquo;Project Omega&rdquo; May Be Set to Mint New Millionaires. Here&rsquo;s How to Get In.</a>
					</li>
																<li>
						<a href="https://investorplace.com/2024/04/legendary-investor-predicts-forget-a-i-this-technology-is-the-future/?cid=MKT794457&amp;eid=MKT802109">Legendary Investor Predicts: &ldquo;Forget A.I. THIS Technology Is the Future&rdquo;</a>
					</li>
									</ul><div>
			<div></div>
						<div></div>
					</div>
	The post <a href="https://investorplace.com/earning-results/2024/05/nmtc-stock-earnings-neuroone-medical-tech-for-q2-of-2024/">NMTC Stock Earnings: NeuroOne Medical Tech Misses EPS, Misses Revenue for Q2 2024</a> appeared first on <a href="https://investorplace.com">InvestorPlace</a>.

NMTC Stock Earnings: NeuroOne Medical Tech Misses EPS, Misses Revenue for Q2 2024

NeuroOne Medical Technologies Corporation (NMTC) Q2 2024 Earnings Call Transcript

NeuroOne Medical files $150M mixed securities shelf

<a href="https://investorplace.com">InvestorPlace - Stock Market News, Stock Advice &amp; Trading Tips</a>
If the prospect of controlling computers and robots with brainpower alone excites you, neurotech stocks are right up your alley. Unfortunately, today&rsquo;s top neurotech company &mdash; Elon Musk&rsquo;s Neuralink &mdash; remains off-limits to retail investors. But that doesn&rsquo;t mean there isn&rsquo;t plenty of opportunity elsewhere in public markets.



Neurotech stocks are in a somewhat tricky position for all but the most speculative and risk-on investors; the sector is ascendant, true, but combines the volatility of <a href="https://investorplace.com/industries/healthcare/biotech/">biotech stocks</a> with the inherent risk of small-cap tech startups. At the same time, these companies are often pre-revenue and R&amp;D-intensive, which creates a unique series of cash flow problems that could bankrupt even the most promising neurotech stock.



To that end, these neurotech stocks have some of the best potential among an admittedly small field &mdash; but they&rsquo;re riskier than more mundane options, even if the potential rewards outweigh the negatives.



<h2>NeuroOne Medical Technologies (NMTC)</h2>



<div><img width="300" height="169" src="https://investorplace.com/wp-content/uploads/2022/10/biomedical-technology1600-300x169.png" alt="Modern Medical Research Laboratory with Computer, Microscope, Glassware with Biochemicals on the Desk. Scientific Lab Biotechnology Development Center Full of High-Tech Equipment. Biomedical technology stocks, RSLS Stock"><div>Source: Gorodenkoff / Shutterstock.com</div></div>NeuroOne Medical Technologies (NASDAQ:<a href="https://investorplace.com/stock-quotes/nmtc-stock-quote/">NMTC</a>) is one of today&rsquo;s best options among neurotech stocks, as the firm&rsquo;s <a href="https://nmtc1.com/technology">proprietary electrodes</a> are thin and flexible enough to map easily onto the human brain (relatively and comparatively speaking, that is). NeuroOne&rsquo;s current ambitions don&rsquo;t yet scale to Musk&rsquo;s, but that&rsquo;s a good thing: a small-cap neurotech stock, NeuroOne is starting small and focusing on key healthcare monitoring tasks to pivot upward as cash begins coming in eventually.NeuroOne&rsquo;s primary current core offerings is OneRF, which helps monitor and detect seizures for epileptic patients.



But they aren&rsquo;t stopping there.



Last year, NeuroOne unveiled plans to <a href="https://www.drugdeliverybusiness.com/neuroone-pursuing-drug-delivery-neural-probes/">develop drug delivery mechanisms</a> leveraging neural probes, which could prove a boon to many medications that have trouble traversing the notoriously impenetrable blood-brain barrier. If the plans come to fruition, NeuroOne could be a major contributor to patient outcomes across a range of healthcare applications.



<h2>Neuronetics (STIM)</h2>



<div><img width="300" height="169" src="https://investorplace.com/wp-content/uploads/2022/07/biopharma-1600-300x169.jpg" alt="Illustration of a biopharma company. Doctor standing in front of various medical icons."><div>Source: Billion Photos / Shutterstock</div></div>Neuronetics (NASDAQ:<a href="https://investorplace.com/stock-quotes/stim-stock-quote/">STIM</a>) treats psychiatric and mental health disorders leveraging neuromodulation tech primarily consisting of transcranial magnetic stimulation, a minimally-invasive outpatient procedure involving external <a href="https://www.mayoclinic.org/tests-procedures/transcranial-magnetic-stimulation/about/pac-20384625">magnetic field application</a>. Its treatment is proven if not widespread, and has <a href="https://neurostar.com/neuronetics/clinical-evidence/">helped more than</a> 175,000 patients nationally over the course of more than 6.4 million treatment applications.



Compared to alternatives, Neuronetics&rsquo; tools maintained durability for twelve months or longer, meaning treatment effects took longer to wear off with fewer visits required. The application also has a shockingly high response rate at 83% and low remission rate of 62%. This may be one major contributor to why most haven&rsquo;t heard of the neurotech stock &mdash; treatments this effective pose a risk to pharma&rsquo;s bottom line, and could ultimately make many existing therapeutics obsolete if the firm&rsquo;s depression treatments continue performing.



Still, Neuronetics is making rapid inroads toward wider adoption, which includes a recent Medicaid win that opens the door to transcranial magnetic stimulation access for <a href="https://ir.neuronetics.com/news-releases/news-release-details/california-medicaid-adds-tms-access-148-million-adolescents-and">more than 14 million</a> adolescents and adults in California.



<h2>Medtronic (MDT)</h2>



<div><img width="300" height="165" src="https://investorplace.com/wp-content/uploads/2018/08/mdtmsn-300x165.jpg" alt="A photo of a Medtronic PLC (MDT) sign outside a building."><div>Source: Shutterstock</div></div>Medtronic&nbsp;(NYSE:<a href="https://investorplace.com/stock-quotes/mdt-stock-quote/">MDT</a>) isn&rsquo;t a pure-play neurotech stock, but it still stands out as having latent potential to secure a sizable chunk of the market as tech advances. The MedTech company is already known for forward-thinking initiatives that include a partnership with Nvidia (NASDAQ:<a href="https://investorplace.com/stock-quotes/nvda-stock-quote/">NVDA</a>) to develop AI-enabled diagnostics. Assuming that Medtronic will position itself as a neurotech stock as the sector matures is only reasonable.



Medtronic already offers a range of <a href="https://www.medtronic.com/us-en/healthcare-professionals/products/neurological.html">peripheral products</a>, including cranial robotics, deep brain stimulation and spinal cord neurostimulation systems. Morever, Medtronic operates in more than <a href="https://www.medtronic.com/us-en/our-company/key-facts.html">150 countries</a>, all but assuring rapid market penetration as neurotech tools comes to the fore.



Interested investors can even see a possible sneak peek of Medtronic&rsquo;s planned forays into neurotech, as a staff member will be speaking at a July 29th <a href="https://thedaily.case.edu/summer-neurotech-talk/">NeuroTech Talk conference</a>. While Medtronic hasn&rsquo;t sanctioned the talk, nor is it intended to reveal any company-specific plans, it offers an enlightening look into an emerging industry from undeniable experts.



On the date of publication, Jeremy Flint held no positions in the securities mentioned. The opinions expressed in this article are those of the writer, subject to the <a href="http://InvestorPlace.com">InvestorPlace.com</a> <a href="https://investorplace.com/corporate/investorplace-publishing-guidelines/">Publishing Guidelines</a>.



On the date of publication, the responsible editor did not have (either directly or indirectly) any positions in the securities mentioned in this article.
<div>Jeremy Flint, an MBA graduate and skilled finance writer, excels in content strategy for wealth managers and investment funds. Passionate about simplifying complex market concepts, he focuses on fixed-income investing, alternative investments, economic analysis, and the oil, gas, and utilities sectors. Jeremy&rsquo;s work can also be found at <a href="https://jeremyflint.work/">www.jeremyflint.work</a>.</div><h3>More From InvestorPlace</h3>
		<ul><li>
						<a href="https://investorplace.com/2024/04/legendary-investor-predicts-forget-a-i-this-technology-is-the-future/?cid=MKT794457&amp;eid=MKT802109">Legendary Investor Predicts: &ldquo;Forget A.I. THIS Technology Is the Future&rdquo;</a>
					</li>
									</ul><div>
			<div></div>
						<div></div>
					</div>
	
The post <a href="https://investorplace.com/2024/07/3-neurotech-stocks-bridging-mind-and-machine/">3 Neurotech Stocks Bridging Mind and Machine</a> appeared first on <a href="https://investorplace.com">InvestorPlace</a>.

3 Neurotech Stocks Bridging Mind and Machine

<a href="https://investorplace.com">InvestorPlace - Stock Market News, Stock Advice &amp; Trading Tips</a>
Problems with <a href="https://www.labiotech.eu/best-biotech/neuroscience-biotech-companies/">the central nervous system</a> are the second leading cause of death globally, the World Health Organization determined in 2022. One reason for this situation is that it&rsquo;s extremely difficult to develop effective treatments for these disorders because of the complexity of the CNS, European biotech news website Labiotech reported last year. Further, the blood-brain barrier that stops damaging substances from entering our brains also prevents many drugs from impacting the organ. 



In general, finding safe, effective drugs that insurers will pay for and that will be better than standard-of-care treatments is an extremely long, arduous process that&rsquo;s unlikely to succeed. Given the enhanced difficulties involved with developing neurological treatments, companies in that space have an even harder road to traverse. 



But the good news for investors is that, if companies do develop successful neurological drugs, they probably won&rsquo;t face much tough competition. With that in mind, here are the three best neuroscience <a href="https://investorplace.com/industries/healthcare/biotech/">biotech stocks</a> to buy now.



<h2>Vertex (VRTX)</h2>



<div><img width="300" height="169" src="https://investorplace.com/wp-content/uploads/2020/06/vrtx-stock-1-300x169.jpg" alt="Vertex Pharmaceuticals (VRTX) logo visible on display screen"><div>Source: Pavel Kapysh / Shutterstock.com</div></div>Pain is <a href="https://www.arthritis.org/health-wellness/healthy-living/managing-pain/understanding-pain/pain-brain-connection">a neurological phenomenon</a>. Consequently, Vertex&rsquo;s (NASDAQ:<a href="https://investorplace.com/stock-quotes/vrtx-stock-quote/">VRTX</a>) moderate-to-severe acute pain treatment, called suzetrigine, can be viewed as a neurological drug. Importantly, suzetrigine is a <a href="https://www.clinicaltrialsarena.com/news/vertex-aims-for-approval-after-phase-iii-win-with-non-opioid-pain-reliever/">non-opioid pain medication</a>, making it much less addictive than the powerful opioid pain treatments widely used today.



Vertex CEO Reshma Kewalramani explained that his company&rsquo;s drug can &ldquo;potentially fill the gap&rdquo; between very safe but fairly weak painkillers and strong, opioid painkillers that can easily become addictive.



In a Phase-3 trial, suzetrigine successfully reduced patients&rsquo; surgical and non-surgical pain meaningfully more than a placebo. However, it failed to lessen patients&rsquo; pain significantly more than a combination of the opioid drug hydrocodone and acetaminophen.&nbsp;



Nonetheless, GlobalData has estimated that the drug will generate a significant $1.4 billion of revenue for Vertex in 2030. Other analysts believe <a href="https://www.biopharmadive.com/news/vertex-pain-drug-fda-approval-filing-opioid/713568/">that the treatment could</a> generate multi-billion dollar peak annual revenue.



Vertex <a href="https://finance.yahoo.com/news/vertex-announces-advancements-suzetrigine-vx-120000605.html">hoped to finish submitting</a> the drug to the FDA for its approval as a treatment for &ldquo;moderate to severe pain&rdquo; by the end of last quarter.



Given the strong potential of Vertex&rsquo;s non-addictive painkiller, I view it as one of the best biotech stocks to buy at this point. 



<h2>Eisai (ESAIY)</h2>



<div><img width="300" height="169" src="https://investorplace.com/wp-content/uploads/2024/07/alzheimers1600-300x169.png" alt="Alzheimer's disease concept, Elderly woman holding brain symbol of missing jigsaw puzzle, World Alzheimer's, World mental health, Memory loss, Dementia, Parkinson disease."><div>Source: PopTika / Shutterstock.com</div></div>As I&rsquo;ve noted in previous columns, Eisai&rsquo;s (OTCMKTS:<a href="https://investorplace.com/stock-quotes/esaiy-stock-quote/">ESAIY</a>) Alzheimer&rsquo;s drug, Leqembi, <a href="https://www.biospace.com/eisai-biogen-build-case-for-subcutaneous-leqembi-for-alzheimer-s-at-ctad">actually improved </a>the cognition capabilities of 60% of patients thought to be in the early stages of the disease.



Meanwhile, in May Eisai began <a href="https://www.eisai.com/news/2024/news202430.html">a rolling submission</a> of a Biologics License Application (BLA) for a subcutaneous version of the drug. If approved, this version, unlike the intravenous version that&rsquo;s already being utilized, can be administered to patients in doctors&rsquo; offices and in homes. Additionally, the drug can be delivered more quickly via the subcutaneous mechanism than through IV, Eisai reported. Given these points, I believe that the demand for Leqembi will greatly increase after the subcutaenous version of it is released.



By fiscal 2026, Eisai <a href="https://www.fiercepharma.com/pharma/eisai-dials-sales-ambitions-alzheimers-med-leqembi-amid-launch-growing-pains">predicts that the drug&rsquo;s</a> sales can reach almost $2 billion in its fiscal year that ends in March 2027 and $8.8 billion in its fiscal year that ends in March 2033. 



Given Leqembi&rsquo;s strong efficacy and the lack of strong competition in the Alzheimer&rsquo;s treatment space, I believe that the drug&rsquo;s revenue can significantly exceed those targets. Consequently, I believe that the company, which currently has a market capitalization of almost $12 billion, is significantly undervalued and is one of the best biotech stocks to buy now.



<h2>NeuroOne Medical (NMTC)</h2>



<div><img width="300" height="169" src="https://investorplace.com/wp-content/uploads/2022/04/pte_biotech_1600-300x169.png" alt="Medical technology network team meeting concept. Doctor hand working smart phone modern digital tablet laptop computer graphics chart interface, sun flare effect photo, PTE"><div>Source: everything possible / Shutterstock.com</div></div>NeuroOne (NASDAQ:<a href="https://investorplace.com/stock-quotes/nmtc-stock-quote/">NMTC</a>) develops products using thin film electrode technology.&nbsp;Its offerings are being used to facilitate electroencephalograms or EEGs <a href="https://www.mayoclinic.org/tests-procedures/eeg/about/pac-20393875#:~:text=An%20electroencephalogram%20(EEG)%20is%20a,lines%20on%20an%20EEG%20recording.">which determine the extent</a> of electrical activity in the brain. NeuroOne&rsquo;s products are also being used in conjunction with &nbsp;spinal cord stimulation and brain stimulation.



Provoiding significant validation for NeurOne and its products, the firm <a href="https://seekingalpha.com/article/4651466-neuroone-a-hidden-contender-against-clearpoint-in-the-brain-drug-delivery-arena">partners with two </a>very prestigious hospitals, Mayo Clinic and Cleveland Clinic. Additionally, the firm collaborates with a huge medical device company, Zimmer Biomet (NYSE:<a href="https://investorplace.com/stock-quotes/zbh-stock-quote/">ZBH</a>).



Also impressively, NeuroOne is only nine healthcare firms whose stock is owned by the Mayo Clinic.



Moreover, NeuroOne is <a href="https://seekingalpha.com/news/4106153-neuroone-medical-technologies-gaap-eps-of--011">growing at an impressive rate</a> as its product revenue jumped to $1.38 million last quarter compared to $466,000 during the same period a year earlier.



On the date of publication, Larry Ramer held a long position in ESAIY. The opinions expressed in this article are those of the writer, subject to the InvestorPlace.com&nbsp;<a href="https://investorplace.com/corporate/investorplace-publishing-guidelines/" target="_blank">Publishing Guidelines</a>.&nbsp;&nbsp;



On the date of publication, the responsible editor did not have (either directly or indirectly) any positions in the securities mentioned in this article.&nbsp;
<div>Larry Ramer has conducted research and written articles on U.S. stocks for 15 years. He has been employed by The Fly and Israel&rsquo;s largest business newspaper, Globes. Larry began writing columns for InvestorPlace in 2015. Among his highly successful, contrarian picks have been SMCI, INTC, and MGM. You can reach him on Stocktwits at @larryramer.</div><h3>More From InvestorPlace</h3>
		<ul><li>
						<a href="https://investorplace.com/2024/04/legendary-investor-predicts-forget-a-i-this-technology-is-the-future/?cid=MKT794457&amp;eid=MKT802109">Legendary Investor Predicts: &ldquo;Forget A.I. THIS Technology Is the Future&rdquo;</a>
					</li>
									</ul><div>
			<div></div>
						<div></div>
					</div>
	
The post <a href="https://investorplace.com/2024/07/the-3-best-neuroscience-biotech-stocks-to-buy-now/">The 3 Best Neuroscience Biotech Stocks to Buy Now</a> appeared first on <a href="https://investorplace.com">InvestorPlace</a>.

The 3 Best Neuroscience Biotech Stocks to Buy Now

NeuroOne Medical Technologies GAAP EPS of -$0.10, revenue of $825.7M

NeuroOne Medical Technologies Corporation (NMTC) Q3 2024 Earnings Call Transcript

<a href="https://investorplace.com">InvestorPlace - Stock Market News, Stock Advice &amp; Trading Tips</a>
NeuroOne Medical Tech (NASDAQ:<a href="https://investorplace.com/stock-quotes/nmtc-stock-quote/">NMTC</a>) just reported results for the third quarter of 2024.<ul><li>NeuroOne Medical Tech reported earnings per share of -10 cents. This met the analyst estimate for EPS of -10 cents.</li><li>The company reported revenue of $825,776.</li><li>This was 58.71% worse than the analyst estimate for revenue of $2.00 million.</li></ul><div>InvestorPlace Earnings is a project that leverages data from <a href="https://www.tradesmith.com">TradeSmith</a> to automate coverage of quarterly earnings reports. InvestorPlace Earnings distills key takeaways including earnings per share and revenue, as well as how a company stacks up to analyst estimates. These articles are published without human intervention, allowing us to inform our readers of the latest figures as quickly as possible. To report any concerns or inaccuracies, please contact us at <a href="mailto:editor@investorplace.com">editor@investorplace.com</a>.</div><h3>More From InvestorPlace</h3>
		<ul><li>
						<a href="https://investorplace.com/2024/04/legendary-investor-predicts-forget-a-i-this-technology-is-the-future/?cid=MKT794457&amp;eid=MKT802109">Legendary Investor Predicts: &ldquo;Forget AI... THIS Technology Is the Future&rdquo;</a>
					</li>
									</ul>The post <a href="https://investorplace.com/earning-results/2024/08/nmtc-stock-earnings-neuroone-medical-tech-for-q3-of-2024/">NMTC Stock Earnings: NeuroOne Medical Tech Meets EPS, Misses Revenue for Q3 2024</a> appeared first on <a href="https://investorplace.com">InvestorPlace</a>.

NMTC Stock Earnings: NeuroOne Medical Tech Meets EPS, Misses Revenue for Q3 2024

NeuroOne Medical files to sell 5.5M shares of common stock for holders

NeuroOne Medical Technologies ( ($NMTC) ) has shared an announcement. NeuroOne Medical Technologies Corporation has updated the severance benefits ...

NeuroOne Enhances Executive Severance Packages Amid Takeover Possibility

ESAIY

NMTC

STIM

VRTX

Screenshot 2024-05-03 at 5.56.54 PM

Biotech

Interview

NeuroOne – The Medical Device Company That Has Created A Product That Could Monitor And Treat At The Same Time

Screenshot 2024-03-27 at 5.33.58 PM

NeuroOnes&#39;s Innovative Electrode Brain Monitoring Seeks To Provide Insights Into Neurological Disorders

Screenshot 2024-03-07 at 8.32.36 PM

Health Care

Movers & Shakers

ATITK

NeuroOne Medical Technologies&#39; (NASDAQ: NMTC) Innovative Brain Monitoring Tech Developing And Commercializing Electrodes To Provide Insights To Help Physicians Treat Neurological Disorders Like Epilepsy

Press Releases

NeuroOne® Announces First in Human Ablations Completed with OneRF™ Ablation System

NeuroOne® Announces $2.65 Million Equity Financing And $3.0 Million Credit Facility

NeuroOne® to Report Third Quarter Fiscal Year 2024 Financial Results and Provide Corporate Update on August 14

NeuroOne® Reports Third Quarter Fiscal Year 2024 Financial Results and Provides Corporate Update

NeuroOne® to Present at the H.C. Wainwright 26th Annual Global Investment Conference

NeuroOne® Announces Breakthrough Case Completed with OneRF™ Ablation System at the University Hospitals in Cleveland

NeuroOne® Spinal Cord Stimulation Electrode Technology to be Featured at The Business of Pain Conference

NeuroOne® Medical Technologies to Present at the 2024 ThinkEquity Conference

NeuroOne® Announces Expansion of Existing Distribution Agreement with Zimmer Biomet for Commercialization of OneRF™ Ablation System

Events

NeuroOne Medical Technologies Corporation to Present at November 21st Virtual Investor Summit Microcap Event

Comments

NeuroOne Medical Tech

Vendite allo scoperto

NeuroOne Medical Tech (NASDAQ:NMTC) Azioni, Report sulle vendite allo scoperto

Le persone guardano anche

Notizie

PARTNER/COLLABORATORE

BENZINGA NEL MONDO